Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Sponsor
University of Louisville
Study ID
NCT00281021
Phase
PHASE2
Status
Terminated

Conditions

  • Carcinoma, Non-Small Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.

Key Dates

First listed
Jan 24, 2006
Start date
Feb 28, 2006
Status verified
Mar 2018
Primary completion
Dec 31, 2010
Completion
Dec 31, 2010

Study Design

Enrollment
26 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib and Digoxin
    Erlotinib plus Digoxin

Primary Outcome Measure

Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. [ Time Frame: Measured every 6 weeks after baseline until disease progression, an average of 3 months ]

Related Studies